Evidence map›Paper›PMID 40148382›Full record

ArticleScientific reports2025

The preclinical study of biocompatibility of tyrosine polycarbonate bioresorbable scaffold in small caliber porcine peripheral arteries.

Mateusz Kachel, Pedro H C Melo, Yanping Cheng, Gerard B Conditt, Danielle Gram, Jeffrey Anderson, Serge D Rousselle, Sahil A Parikh, Juan F Granada, Grzegorz L Kaluza

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mateusz KachelSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Pedro H C MeloSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Yanping ChengSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Gerard B CondittSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Danielle GramREVA Medical, San Diego, CA, USA.
Jeffrey AndersonREVA Medical, San Diego, CA, USA.
Serge D RousselleStageBio, Mt. Jackson, VA, USA.
Sahil A ParikhSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Juan F GranadaSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Grzegorz L KaluzaSkirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA. gkaluza@crf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-eluting resorbable scaffolds (DRS) are conceptually attractive for treatment of peripheral arterial disease, particularly below-the-knee. MOTIV is a peripheral variant of REVA Medical's well-established, radiopaque tyrosine-polycarbonate (Tyrocore) sirolimus-eluting DRS. The purpose of this study was to provide imaging and histopathologic data on vascular response to MOTIV in porcine peripheral arteries. MOTIV scaffolds (3.0 or 3.5 × 12/24/36/48/60 mm) were implanted in 20 internal iliac arteries of 9 Yorkshire swine. At 30 and 90 days, vascular stenosis, strut coverage, and strut apposition were characterized using optical coherence tomography. Scaffold structure and vascular healing were assessed by histopathology and scanning electron microscopy. At termination, all vessels remained patent. The average neointimal thickness was 0.22 ± 0.05 mm in Group 1 (30 days) and 0.18 ± 0.10 mm in Group 2 (90 days); the percent area stenosis was 28 ± 6% and 24 ± 11%, respectively. All struts were fully covered by neointima. No malapposition, stent fracture or late strut discontinuity was observed. Adequate vessel wall healing at both time points was characterized by a typically fully mature neointima and complete reendothelialization at all sites. No unresorbed luminal thrombus was observed. The inflammation scores were low for all vessels on both time points, except for one animal. The average inflammation (excluding multinucleated giant cells [MNGCs]) was 0.6 (MNGCs score was 0.9) for the stented vessel segments at 30 days and 0.8 (MNGCs score of 1.0) at 90 days. Implantation of the MOTIV up to 60 mm long in small-caliber peripheral arteries of swine resulted in 100% patency rate and adequate vascular healing at 30-day and 90-day timepoints. The Tyrocore-based DRS retained the necessary structural integrity throughout the course of the study and confirmed their favorable biocompatibility in small-caliber porcine peripheral arteries.

Indexed as

Absorbable ImplantsBiocompatible MaterialsDrug-Eluting StentsIliac ArteryPolycarboxylate CementTissue ScaffoldsTyrosineAnimalsNeointimaPeripheral Arterial DiseaseSirolimusSwineTomography, Optical CoherenceBiocompatible MaterialspolycarbonatePolycarboxylate CementSirolimusTyrosineAnimal modelBelow-the-kneeBioresorbable scaffoldsChronic limb threatening ischemiaPeripheral arterial diseaseTyrocore

Identifiers

PMID40148382
PMCPMC11950639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.